Method for activating the lipid catabolic metabolism in enteric epithelium and improving the lipid metabolism in enteric epithelium

Abstract

Disclosed are a method for activating lipid metabolism in the small intestine epithelium and also a method for promoting accumulation of fatty acids into the small intestine epithelium, each of which features administering an effective amount of a diacylglycerol. Also disclosed are methods for improving various symptoms in diabetes, which have ingesting a diacylglycerol. Ingestion of the diacylglycerol leads to α-cumulation of the fatty acids in the small intestine. The fatty acids so accumulated promote induction of β-oxidation, thereby not only activating lipid catabolism but also making it difficult to allow lipids to accumulate as triacylglycerols. This series of actions eventually results in development of lowering action for blood remnant-like lipoprotein level and also lowering action for blood leptin level, and hence, lipid metabolism is improved. Further, energy consumption is enhanced by promoting the induction of β-oxidation and activating lipid catabolism.

1 . A method for activating lipid catabolism in the small intestine epithelium, which comprises administering an effective amount of a diacylglycerol.  
     
     
         2 . The method according to  claim 1 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         3 . The method according to  claim 1  or  2 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         4 . A method for promoting accumulation of fatty acids into the small intestine epithelium, which comprises administering an effective amount of a diacylglycerol.  
     
     
         5 . The method according to  claim 4 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         6 . The method according to  claim 4  or  5 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         7 . A method for inducing expression of a small intestine lipid metabolic gene, which comprises administering an effective amount of a diacylglycerol.  
     
     
         8 . The method according to  claim 7 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         9 . The method according to  claim 7  or  8 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         10 . A method for suppressing synthesis of a triacylglycerol in the small intestine epithelium, which comprises administering an effective amount of a diacylglycerol.  
     
     
         11 . The method according to  claim 10 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         12 . The method according to  claim 10  or  11 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         13 . A method for promoting energy consumption, which comprises administering an effective amount of a diacylglycerol.  
     
     
         14 . The method according to  claim 10 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         15 . The method according to  claim 13  or  14 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         16 . A method for lowering a serum RLP level, which comprises administering an effective amount of a diacylglycerol.  
     
     
         17 . The method according to  claim 16 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         18 . The method according to  claim 16  or  17 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         19 . A method for lowering a serum leptin level, which comprises administering an effective amount of a diacylglycerol.  
     
     
         20 . The method according to  claim 19 , wherein 15 to 90 wt. % of constituent fatty acids of said diacylglycerol comprise ω3 unsaturated fatty acids.  
     
     
         21 . The method according to  claim 19  or  20 , wherein 1,3-diacylglycerols in said diacylglycerol amount to at least 50 wt. % of the whole diacylglycerol.  
     
     
         22 - 32 . (canceled)  
     
     
         33 . A medical food for a diabetic patient, comprising a diacylglycerol.  
     
     
         34 . A processed oil or fat food having insulin resistance improving effect, comprising a diacylglycerol.